Endocrine Abstracts (2017) 49 EP174 | DOI: 10.1530/endoabs.49.EP174

Jejunum/ ileum Neuroendocrine Tumours: results of a multicentric retrospective study

Ana Paula Marques1, Ana Paula Santos2, Isabel Claro3, Ana Cristina Sanches2, Isabel Fernandes5, José Manuel Lopes6, John Preto6, Fernando Rodrigues7, Ana Luisa Catarino8, Juan Mellidez9, Bernardo Pereira10, Gustavo Rocha11, Maria João Bugalho5 & Grupo Estudos Tumores Neuroendócrinos12


1Hospital Pedro Hispano, Matosinhos, Portugal; 2Instituto Português Oncologia, Porto, Portugal; 3Instituto Português Oncologia, Lisboa, Portugal; 4Instituto Português Oncologia, Porto, Portugal; 5CHLN, Lisboa, Portugal; 6CHSJ/IPATIMUP, Porto, Portugal; 7Instituto Português Oncologia, Coimbra, Portugal; 8HBA, Loures, Portugal; 9HSP, Aveiro, Portugal; 10HGO, Almada, Portugal; 11CHVNG, Vila Nova de Gaia, Portugal; 12Portugal, Portugal, Portugal.


Introduction: The Neuroendocrine Tumors Study Group of the Portuguese Endocrine Society (SPEDM) performed the first observational study between November 2012 and July 2014 too assess the profile of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) patients (pts) followed at the main Portuguese hospitals. Several demographic and clinical data were collected

Objective: Characterize the clinicopathological features and treatment of patients with NET originating in the jejunum and ileum.

Material and methods: Included 71 pts with ≥18 years and a confirmed diagnosis of jejunum /ileum NET based on histopathology/cytology findings.

Results: Mean age was 57.2 (32–83) years, 61% (n=43) males. Most tumors 89% (n=63) were located at the ileum; two were multifocal. Ki67 was available in 86% of pts, 64% G1. At diagnosis 91% (51/56) had lymph node metastases and 70% (43/61) distant metastases.

The most common symptom, available in 59 pts, was abdominal pain in 49% (29/59). Serum Chromogranin A (Crg A) was available in 65% (46/71) and was 2×≥ upper limit of normal in 61%(28/46). Urinary 5HIAA checked in 61% (43/71) was elevated in 56%(24/43), 86% of these with distant metastases. CT scan was the preferred radiologic procedure in 87% of pts. Nuclear medicine imaging, either octreotide scan or 68 Ga-DOTA-NOC Pet Scan was used in 75%(53/71) of pts Tumor size known in 58 pts was 24±14.7 mm. Primary tumor surgery was performed in 90 and 32% did surgery of hepatic metastases. 62% of the pts received somatostatin analogues(SA), two were treated with SA and interferon and two with systemic chemotherapy. 11 cases were submitted to hepatic transarterial embolization. Peptide Receptor Radionuclide Therapy with 177Lu was done in 9%.

Conclusions: This paper reveals important information regarding clinical practice. Most of our pts presented with well differentiated tumors but in an advanced stage. Regarding therapy there was an extensive use of surgery and systemic treatment mainly with SA.